The key to driving down costs, or at the very least making costs more predictable, is integrating pathways into the Oncology Care Model program, said John L. Fox, MD, MS, associate vice president of medical affairs at Priority Health.
The key to driving down costs, or at the very least making costs more predictable, is integrating pathways into the Oncology Care Model program, said John L. Fox, MD, MS, associate vice president of medical affairs at Priority Health.
Transcript (slightly modified)
Can we draw parallels between payer-driven clinical pathways and the Oncology Medical Home model?
Medicare's Oncology Care Model, which I’m not an expert on, I think has a potential to drive down the cost of healthcare without impacting patient outcomes. There are a number of ways that can happen. One is that the cost of care will become more predictable because the regimens that providers use will have a more predictable cost.
In our experience with our Oncology Medical Home Initiative, where we ask providers to develop pathways around high-volume conditions and not only pathways but preferred regimens, we very clearly showed that providers tended to choose the less costly regimens. So I think that integration of pathways into an oncology care model program is not only essential, but that’s what will help drive down costs, at least make costs more predictable.
But more importantly, I think the pathways have to include or embed advanced care planning. The trends for increasing costs of drugs don’t suggest that will drive down the costs of care simply by having pathways. But if those pathways include discussions of patient preferences and goals of care, then I think it increases the likelihood that will diminish the amount of chemotherapy we’ll give to patients at the end-of-life because they’ll have said, my goals can be obtained in ways other than chemotherapy.
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More